drugset / Trial / NCT02082236

Pharmacokinetics of Sufentanil Sublingual Microtablet 30 mcg and 15 mcg in Healthy Subjects

NCT02082236

Phase 1 Completed 40 enrolled Talphera, Inc
RandomizedCrossoverOpen-labelBasic science

Summary

The purpose of this study is to establish the single and multiple-dose pharmacokinetics (PK) of sublingual administration of the Sufentanil Sublingual Microtablet (SSM) 30 mcg and compare the pharmacokinetics of a single dose of SSM 30 mcg to 2 doses of SSM 15 mcg administered 20 minutes apart.

Timeline

Start
2014-05
Primary completion
2014-05
Completion
2014-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Sufentanil Other / unclassified 15 ug Other
Subject Sufentanil Other / unclassified 30 ug Other

Indications

No indication recorded.